– CANADA, Vancouver – BetterLife Pharma Inc. (CSE: BETR | OTC: BETRF | FRA: NPAU), an emerging biotech company, today announced the appointment of Henri Sant-Cassia, co-founder of The Conscious Fund, to its Board of Directors.
“We are extremely pleased to welcome Henri Sant-Cassia to our Board of Directors. He brings a wealth of experience in the psychedelic space, which will be very valuable as we execute our plans to develop non-hallucinogenic compounds to treat depression and other mental health disorders. We look forward to working with The Conscious Fund team and their extensive network within the psychedelic community,” said CEO, Ahmad Doroudian.
BetterLife also announced the resignation of Sergei Stetsenko from its Board of Directors. The Company thanks Mr. Stetsenko for his contributions to BetterLife.
About Henri Sant-Cassia
Henri Sant-Cassia has 10 years of experience working in the plant medicine field and has been a serial entrepreneur since his early twenties. Since 2018, he has been a founding partner at The Conscious Fund, the most active venture fund in the psychedelic medicine space. His expertise includes psychedelic compounds, operating models, venture funding, growth, and exit planning, as well as managing media and investor relations campaigns. His work has created over $200 million in company valuations within the psychedelic world, and he previously worked in the manufacturing, retail, and research of cannabinoid-based products.
“I am delighted to be working with Ahmad, who is one of the new breeds of CEOs from the bioscience space, and Patrick, one of the longest-serving members of the psychedelic medicine community. We believe that BetterLife has enormous untapped potential, both within second-generation psychedelic therapies and in the wider medical field,” commented Mr. Sant-Cassia.
He holds a degree in law from University College London. Mr. Sant-Cassia also serves on the boards of Magic Med and Microdose, a media company.
About The Conscious Fund
The Conscious Fund is the most active early-stage venture fund in the psychedelic medicine space. It invests in drug discovery, clinics, addiction programs, retreats, AI, telemedicine, media, and training. Its global, platform-based approach helps to transform outcomes for patients with mental health, addiction, and chronic pain issues.
The $60 million fund has backed 14 of the leading companies in the sector, spanning drug discovery, clinics, addiction, AI, and media, and has incubated 13 projects, including The Psychedelic Medicine Association, the first psychedelic medicine SPAC, and Microdose, a profitable media company.
For more information: https://theconscious.fund/
About BetterLife Pharma Inc.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumors to treat specific types of cancer.
For more information: https://abetterlifepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.